

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

Annual Benefit Report of Beta Bionics, Inc.

(October 21, 2015 - December 31, 2015)

Beta Bionics, Inc. (the “Company” or “Corporation”) was incorporated as a Massachusetts benefit corporation on October 21, 2015. This Annual Benefit Report is prepared in accordance with Chapter 156E of the Massachusetts General Laws, Section 15 and covers the Company’s activities through December 31, 2015.

Our General and Specific Public Benefit and Mission

The Company has the stated purpose of creating a general public benefit as well as a specific public benefit of improving public health. To that end, the Company’s Board of Directors adopted and approved comprehensive bylaws enumerating and explaining the manner in which the Company will pursue its specific public benefit purpose for the type 1 diabetes (“T1D”) community. The bylaws establish the following four guiding principles of the Company’s public benefit:

1. To provide and to protect the Corporation’s turnkey solutions for safe and effective autonomous glycemic control;
2. To bring the Corporation’s technology to as many people with T1D as possible in an expeditious and responsible manner;
3. To continue to innovate and to offer the latest advances as expeditiously and responsibly as possible; and
4. To act in the best possible interest of the T1D community in connection with fulfilling the Corporation’s functions.

Actions to Accomplish General and Specific Public Benefit

The Company pursued its general and specific public benefit and mission during the short timespan from October 21, 2015 through December 31, 2015 by successfully negotiating and licensing the intellectual property related to the bionic pancreas technology from Boston University. Additionally, the Company successfully negotiated and secured an initial round of investment with Eli Lilly & Company to capitalize Beta Bionics and position itself to begin operations in 2016. These foundational steps allow the Company to ultimately seek regulatory approval and commercialize its technology, which serves the Company’s general and specific public benefit mission.

No Hindrance to Creation of Public Benefit

No circumstances were present in 2015 that hindered the Company’s creation of its general or specific public benefit.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

B-Lab's Selection as the Third Party Standard

Shortly upon incorporation, the Company selected B-Lab (www.bcorporation.net), a non-profit organization that certifies benefit corporations via its B Impact Assessment and B Analytics tools to measure and manage positive impact. B Lab is the most widely recognized and rigorous third party standard for certifying and measuring corporate public benefit and sustainability performance.

Social and Environmental Performance Based on B-Corp Standard

- *Corporation Comparative Analysis*

As of the end of 2015, Beta Bionics had not yet earned B Corporation certification because it is not yet able to complete the assessment, which asks many operations-related questions. As of the end of 2015, the time-frame covered by this report, Beta Bionics was still in the capital formation stage and has little or no operations to analyze. However, Beta Bionics is working diligently to build a B Corporation-compliant enterprise that will excel according to the B Lab Impact Assessment. A summary of our planning activities lies below.

- *Governance*

Where other companies may focus only on return on investment, our Corporation, though its executives and the Board of Directors (the "Board"), is committed both to our shareholders and to the T1D community and will work to ensure that the Corporation's bionic pancreas technology is protected and available for their benefit. The Corporation's leadership will be ever mindful that it was founded by parents deeply affected by T1D to help not only their children, but all children and adults struggling to live with T1D and their loved ones who support them. In carrying out the Corporation's purpose of creating a general and specific public benefit, as identified above.

The Company's Board and executive team will meet on at least an annual basis to review the Company's social and environmental performance and to determine whether the Company is meeting its objectives.

- *Workers*

As of December 31, 2015, Beta Bionics had no non-founder workers and, like many certified B Corporations, is exempt from this portion of the assessment until it hires employees.

- *Community*

Beta Bionics is actively involved in the T1D community and is partnering with like-minded educational institutions, not-for-profit entities and socially-minded companies to educate the public about T1D management and the Company's

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

bionic pancreas technology. In 2015, the Company's President, Ed Damiano, gave presentations and talks on the bionic pancreas technology to various groups and organizations throughout the world.

- *Environment*

The Company strives to be environmentally responsible and, as we begin operations, will look at every area of our environmental impact, including energy use, water consumption and waste and plans on putting in place a robust series of practical measures designed to address each of these areas. As December 31, the Company had implemented an online document management system to reduce our reliance on paper.

- *Impact Business Models*

The Company benefit consumers by providing education, support and eventually the bionic pancreas technology to alleviate the burdens of T1D management.

We believe our status as a public benefit corporation and commitment to the public benefit purpose and focus on transparency, is going to make all the difference in the way we do business and, ultimately, will result in a healthier and happier T1D community.

Meet our Public Benefit Director and Public Benefit Officer

The Company's Benefit Director is Jeff Hitchcock, founder of the not-for-profit Children with Diabetes and a father of a now adult daughter with T1D. Edward Raskin, an attorney and father of a 9-year old son with T1D, serves as the Company's Benefit Officer.

Correspondence relating to this report may be directed to either individual at Beta Bionics, Inc., Business Innovation Center, Photonics Center, 8 Saint Mary's Street, Suite 936, Boston, MA 02215-2421.

No Compensation for Board Positions

The Company has not, provided compensation to the members of its Board of Directors for services performed in their roles as members of the Board.

Owners of 5% or More of the Company's Outstanding Shares

The following persons or entities own five percent or more of the outstanding shares of the Company's stock: (1) Edward R. Damiano; (2) Toby Milgrome; (3) Firas El-Khatib; (4) the Trustees of Boston University; and (5) Eli Lilly & Company.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

No Connection Between B-Lab and the Company

B-Lab, including its directors, officers, and those holding of 5% of more of the governing interest in B-Lab, have no connection with the Company, including the Company's directors, officers, and those holding of 5% of more of the governing interest in the Company.

Powers of the Board Have Not Been Dispensed with or Restricted

The Company has not dispensed nor restricted the discretion of the Board.

Certification of the Company's Benefit Director

I, Jeff Hitchcock, certify that I am the duly elected Benefit Director of Beta Bionics, Inc. At no time have I held, nor do I currently hold, any other positions within the Company. I have not received any compensation for my services as a Benefit Director of Beta Bionics, Inc. I have reviewed the Company's public benefit report and certify as to the accuracy of its contents. The Company has acted in accordance with its general public benefit as well as its specific public benefit purpose in all material respects during the period covered by this report. I further certify that the directors and officers have complied with subsection (a) of Section 10, subsections (a) to (g) of section 11, and subsection (a) of Section 12 of Chapter 156E of the Massachusetts General Laws. In my opinion, the Company's benefit status has and will continue to have a positive impact on its business including creating a positive consumer opinion, increasing return on investment, positively impacting shareholders and its employees as well as the T1D community.

Executed on this 1st day of April 2016,



JEFF HITCHCOCK